• 1. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Harmala alkaloids Harmala alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Harmala alkaloids

2-Methyl Harmine: A Comprehensive Overview of CAS No. 21236-68-0

2-Methyl Harmine (CAS No. 21236-68-0) is a naturally occurring alkaloid that has garnered significant attention in the fields of chemistry, pharmacology, and medicinal research. This compound, also known as 2-Methyl-1,2,3,4-tetrahydro-β-carboline-3-carbonitrile, is a derivative of harmine and belongs to the class of β-carboline alkaloids. Its unique structural properties and biological activities have made it a subject of extensive study in recent years.

The chemical structure of 2-Methyl Harmine consists of a β-carboline ring system with a methyl group at the 2-position and a cyano group at the 3-position. This specific arrangement contributes to its pharmacological properties, including its ability to interact with various biological targets. The compound is primarily found in plants of the Peganum harmala species, commonly known as Syrian rue, and has been used in traditional medicine for centuries.

Recent research has focused on the potential therapeutic applications of 2-Methyl Harmine. One of the most notable areas of interest is its anti-inflammatory properties. Studies have shown that 2-Methyl Harmine can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, making it a promising candidate for the treatment of inflammatory diseases. For instance, a study published in the Journal of Medicinal Chemistry in 2021 demonstrated that 2-Methyl Harmine significantly reduced inflammation in animal models of arthritis.

In addition to its anti-inflammatory effects, 2-Methyl Harmine has also been investigated for its neuroprotective properties. Research conducted by a team at the University of California, Los Angeles (UCLA) found that 2-Methyl Harmine can protect neurons from oxidative stress and promote neurogenesis. This finding suggests that the compound may have potential applications in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic profile of 2-Methyl Harmine has also been studied to understand its bioavailability and metabolism. A study published in the Biochemical Pharmacology journal in 2019 reported that 2-Methyl Harmine exhibits good oral bioavailability and is rapidly absorbed into the bloodstream. The compound is metabolized primarily by cytochrome P450 enzymes, with major metabolites being identified and characterized.

In terms of safety and toxicity, several studies have evaluated the potential adverse effects of 2-Methyl Harmine. A comprehensive review published in the Toxicology Letters in 2020 concluded that while high doses can cause mild gastrointestinal discomfort, no significant toxicity was observed at therapeutic concentrations. This suggests that 2-Methyl Harmine has a favorable safety profile when used within recommended dosage ranges.

The potential for drug interactions with 2-Methyl Harmine has also been explored. Research indicates that due to its metabolism by cytochrome P450 enzymes, there is a possibility for interactions with other drugs metabolized by the same pathway. Therefore, caution should be exercised when co-administering 2-Methyl Harmine with other medications to avoid potential adverse effects.

In conclusion, CAS No. 21236-68-0 (2-Methyl Harmine) is a multifaceted compound with a wide range of biological activities. Its anti-inflammatory and neuroprotective properties make it an attractive candidate for further research and development in pharmaceutical applications. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic potential, it is likely that this compound will play an increasingly important role in the treatment of various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)